LABU240927C139000
- 0.01
- -0.03-75.00%
Direxion Daily S&P Biotech Bull 3x Shares ETF Newsroom
(ABBV) - Analyzing AbbVie's Short Interest
Absence of Black Box Warning For Bristol Myers' Schizophrenia Treatment Could Enhance Alzheimer's Psychosis Potential
CNBC Halftime Report Final Trades: Meta Platforms, Accenture, AbbVie, The Walt Disney Company
Here's How Much You Would Have Made Owning AbbVie Stock In The Last 10 Years
Exact Sciences, Quanterix Extend Slide After Medicare Rates
Exact Sciences Analyst Ratings
Looking Into Alnylam Pharmaceuticals's Recent Short Interest
Amgen Stock Slides 5% as Analysts Weigh in on Drug Study Results
Here's How Much $1000 Invested In United Therapeutics 5 Years Ago Would Be Worth Today
Top 4 Health Care Stocks That May Keep You Up At Night
Overweight Quality Stocks With Positive EPS Revision - MS
UCB Gets Expanded FDA Approval for Psoriasis Drug Bimzelx
Gilead Sciences Recalls One Lot Of Its COVID-19 Treatment Due To Presence Of Glass Particles
FDA Says Gilead Issues Voluntary Nationwide Recall Of One Lot Of Veklury For Injection 100 Mg/Vial Due To The Presence Of A Glass Particle
United Therapeutics Analyst Ratings
Sharp Sword! The FTC sues three major pharmaceutical 'middlemen', vowing to correct the distorted chain of interests.
①The USA FTC announced on its official website that it has filed a lawsuit against three major pharmaceutical benefit managers and their affiliated organizations, accusing them of engaging in anti-competitive and unfair rebate practices; ② The FTC also "explicitly stated" in the declaration that it is deeply concerned about the roles played by Eli Lilly, Novo-Nordisk, and Sanofi, insulin pharmaceutical companies, and may suggest in future enforcement actions to prosecute these pharmaceutical manufacturers.
Bristol-Myers Acquired Drug KarXT Poised For FDA Approval As First New Type Of Schizophrenia Treatment In 70 Years
Spotlight on AbbVie: Analyzing the Surge in Options Activity
Gilead Sciences Unusual Options Activity For September 20
Wall Street's Most Accurate Analysts Weigh In On 3 Health Care Stocks With Over 3% Dividend Yields